Pharmaceutical industry
Roche buys US biotech company 89Bio in a billion-off deal
The Swiss pharmaceutical giant digs deeply into the pocket: What is behind the billion dollar purchase of 89BIO – and why is an American’s active ingredient candidate considered hope for liver diseases?
The Swiss pharmaceutical company Roche takes over the US biotech company 89Bio for up to $ 3.5 billion. According to Roche, the company does pioneering work in the development of innovative therapies to treat liver diseases.
The main product of 89BIO is the active ingredient candidate Pegozafer appointment, which is in a late development phase, as Roche announced. Admission -relevant studies on the treatment of steatohepatitis are currently being carried out. Steatohepatitis is a severe and widespread inflammatory liver disease that occurs in connection with fat accumulation in the liver, a frequent commentary on obesity.
Roche strengthens portfolio with 89Bio
The takeover of Roche’s portfolio in the area of cardiovascular, kidney and metabolic diseases, emphasized the Basler in their message. It also opens up opportunities for future combination therapies.
Roche pays $ 14.50 per 89 bio share in cash, which is around $ 2.4 billion. In addition, the shareholders receive a special additional payment right of up to $ 6 per share, which could increase the total value of the takeover to up to $ 3.5 billion. The equivalent of this is up to 3 billion euros.
dpa
Source: Stern
